NasdaqGS:AMGNBiotechs
Is It Time To Revisit Amgen (AMGN) After The Recent 4.6% Share Price Pullback
Wondering whether Amgen at around US$351 per share still offers value, or if most of the opportunity is already priced in.
The stock has returned 0.9% over the past week, 7.1% year to date, and 26.6% over the last year, with a 4.6% decline across the past month that may have shifted how some investors think about its risk and return profile.
Recent headlines have focused on Amgen's position within the large cap biotech space, including ongoing attention on its product portfolio and pipeline...